[System mastocytosis: presentation of a case evolving into myelofibrosis and no response to interferon alfa 2b].
de las Nieves
M
M
Poveda
F
F
Queipo de Llano
M P
MP
González-Hermoso
C
C
D001853:Bone Marrow / Q000473:pathology; D002543:Cerebral Hemorrhage / Q000209:etiology; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007665:Ketotifen / Q000627:therapeutic use; D008415:Mastocytosis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000209:etiology* / Q000473:pathology; D011379:Prognosis; D011994:Recombinant Proteins; D013156:Splenectomy
D006633:Histamine Antagonists; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011241:Prednisone; D007665:Ketotifen